| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978293 | Bulletin du Cancer | 2016 | 4 Pages |
Abstract
Chemotherapy with docetaxel has remained a cornerstone of second-line treatment for more than 15 years, but it is associated with an unfavorable safety profile. Recently, the results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check- Mate-057, have deeply changed our current clinical practice and open the debate for further improvements in the clinical care of lung cancer. This paper explores the recent findings about nivolumab in the second-line setting and discusses future directions for nivolumab and other immune Oncology drugs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Denis Moro-Sibilot, Léonie Ferrer, Matteo Giaj Levra, Anne Claire Toffart,